Table 1 Patient demographic and clinical characteristics
Demographics | |
|---|---|
Age (y) Median (Q1; Q3) | 48 (45; 51) |
Gender n (%) | |
Female | 14 (30.4) |
Male | 32 (69.6) |
BMI Median (Q1; Q3) | 22.4 (19.8; 24.3) |
Overweight (BMI > =25) n (%) | 8 (17.4) |
Chronic alcohol abuse n (%) | 15 (34.1) |
Cirrhosis n (%) | 6 (13) |
Child Pugh stage n | 6 |
A n (%) | 6 (100) |
B, C, D n | 0 |
HIV treatment | |
Protease inhibitors n (%) | 28 (60.9) |
Integrase inhibitors n (%) | 3 (6.5) |
Non-nucleoside RT inhibitors n (%) | 8 (17.4) |
Other treatment n (%) | 7 (15.2) |
HCV treatment | |
None, n (%) | 28 (60.9) |
Previous treatment failure n (%) | 10 (21.7) |
Previous sustained virologic response n (%) | 8 (17.4) |
Virology | |
HCV genotype n (%) | |
1-1a-1b | 24 (59) |
2-3-3a | 9 (22) |
4 41b-4a | 8 (19) |
ND | 5 (10) |
HCV RNA > 15 IU/ml n (%) | 38 (83) |
HCV RNA IU/ml (Q1; Q3) | 1116144 (391800; 3680000) |
Undetectable HIV RNA n (%) | 40 (87) |
CD4/mm3 (Q1; Q3) | 576 (377; 833) |
Liver blood test | |
Delay between ARFI and blood test days (Q1; Q3) | 0 (0; 1) |
AST or ALT ≥2N n (%) | 7 (15.6) |
GGT and/or ALP ≥2N n (%) | 15 (33.3) |
Bilirubin ≥2N n (%) | 10 (22.2) |
US liver characteristics | |
Steatosis n (%) | 3 (6.5) |
Cirrhosis in US n (%) | 6 (13) |
US portal hypertension signs n (%) | 2 (4.3) |
US hepatomegaly n (%) | 14 (30.4) |
US focal liver lesion n (%) | 5 (10.9) |
ARFI characteristics | |
Median (Q1; Q3) (m/s) | 1.29 (1.15; 1.55) |
Min; Max | 0.93; 2.86 |
TE characteristics | |
Median (Q1; Q3) (kPa) | 6.1 (4.6; 7.2) |
Min; Max | 3.4; 35.3 |